George Todorov

IPS
Senior Process Specialist
Mr. Todorov has 11 years of industry experience with early to late-stage process development, IND-enabling studies, supporting external partnerships and consulting in the Cell Therapy and AAV Gene Therapy space. Before joining IPS, he directed a process group developing novel AAV manufacturing and analytical platforms through the evaluation of new technologies and continuous process improvement projects. George developed and implemented an AAV process scale-up for transient expression systems in mammalian cells, leveraging DOE yield optimization studies. His hands-on and consulting experience includes designing and coordinating laboratory expansions and GMP facilities for various Cell Therapy and AAV process scale-up operations. George is a meticulous, inquisitive, and data-driven leader focused on empowering and developing teams and organizations. He has trained and managed technical staff in AAV process development and production spanning cell thaw to final formulation.

Related Articles

Repurposing a US Cell Therapy Facility for Flexibility and EU Compliance
Features
Repurposing a US Cell Therapy Facility for Flexibility and EU Compliance

The explosive growth of advanced therapy medicinal products (ATMPs), particularly cellular therapeutics, has driven steady investment in facilities capable of manufacturing these therapeutics at scale . Meanwhile, the industry is collectively moving to adapt to European Union Annex 1 standards, which places a more stringent emphasis on contamination control.